We are international
Donate
TEXT SIZE   


Phase I Study of Elotuzumab (HuLuc63) in Combination with Bortezomib in Relapsed Multiple Myeloma
XIIth International Myeloma Workshop in Washington, DC
Andrzej Jakubowiak, M.D.
University of Michigan Cancer Center
Ann Arbor, Michigan
02.23.09



XIIth International Myeloma Workshop in Washington, DCOn-Demand Only
Session: Clinical - New Agents
Chairs: Alok Sharma, M.D., Meletios Dimopoulos, M.D.

February 27, 2009, 13:30 - 13:45 Eastern Standard Time


Phase I Study of Elotuzumab (HuLuc63) in Combination with Bortezomib in Relapsed Multiple Myeloma
Dr. Andrzej Jakubowiak
University of Michigan Cancer Center, Ann Arbor, Michigan

 


Back to the Meeting Index


 related articles